Quarterly report pursuant to Section 13 or 15(d)

Schedule of Diluted Net Income (Loss) Per Share (Details)

v3.21.2
Schedule of Diluted Net Income (Loss) Per Share (Details) - shares
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total contingent shares issuance arrangement, stock options or warrants 182,716,716 182,606,942
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total contingent shares issuance arrangement, stock options or warrants 540,206 736,260
Common Stock Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total contingent shares issuance arrangement, stock options or warrants 473,609 154,178
Share-based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total contingent shares issuance arrangement, stock options or warrants 3,401 17,004
Series A Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total contingent shares issuance arrangement, stock options or warrants 1,300,000 1,300,000
Series C Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total contingent shares issuance arrangement, stock options or warrants 180,399,500 180,399,500